Effectiveness of MST Versus ECT for Major Depressive Episode

Status Not yet recruiting

Clinical Trial Summary

Despite advancements in Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) for Major Depressive Disorder (MDD), there remains a need for further research to replicate clinical outcomes and understand the therapeutic targets of these treatments. This study aims to address these gaps through a double-blinded, randomized, non-inferiority investigation comparing the efficacy, tolerability, cognitive adverse effects, and neurophysiological biomarkers of MST and bilateral ECT in patients with MDD.

Clinical Trial Description

Participants will be randomly allocated to either the ECT or MST group. Each center aims to recruit 30 participants for each group, using block randomization, resulting in a total of 30 participants per group. The trial comprises a 12-session intervention phase of ECT/MST, spanning approximately 4 weeks, followed by a 12-week observation period. For the first three treatment sessions, participants will receive consecutive sessions. Subsequently, there will be a one-day interval between sessions 4 to 6, a two-day interval between sessions 7 to 9, and a three-day interval between sessions 10 to 12, ensuring completion within a month. Following treatment completion, participants will undergo follow-up clinical observations every four weeks for 12 weeks. EEG and ECG recordings will be obtained at baseline, post-session 3, 6, 9, 12 (3 hours after each session), and at the 12-week follow-up. All evaluations will be conducted under standardized conditions throughout the sessions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06409325
Study type	Interventional
Source	Shanghai Mental Health Center
Contact	TianHong Zhang, Doctor
Phone	13127577024
Email	zhang_tianhong@126.com
Status	Not yet recruiting
Phase	N/A
Start date	August 1, 2024
Completion date	December 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00316160` - Sexual Functioning Study With Antidepressants	Phase 4
Completed	`NCT05416957` - Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets	Phase 1
Active, not recruiting	`NCT03642964` - A Study in Patients With Major Depressive Disorder	Phase 2
Terminated	`NCT01111565` - Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)	Phase 3
Completed	`NCT01912196` - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)	Phase 2
Completed	`NCT00958204` - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression	Phase 3
Completed	`NCT00102492` - Study Of GW679769 In Major Depressive Disorder	Phase 2
Completed	`NCT02012218` - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy	Phase 3
Completed	`NCT01477203` - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders	Phase 4
Completed	`NCT00768430` - Optimization of IV Ketamine for Treatment Resistant Depression	Phase 2
Completed	`NCT00559299` - Patient Tolerability Study of GSK163090	Phase 1
Terminated	`NCT01123707` - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)	Phase 3
Completed	`NCT04403373` - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study	N/A
Completed	`NCT05541302` - Retrospective TMS Therapy for Adults With MDD
Recruiting	`NCT06385405` - Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment	N/A
Completed	`NCT00330616` - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan	Phase 2
Recruiting	`NCT03012724` - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)	N/A
Not yet recruiting	`NCT02395263` - Comparison of Yuxintine With Placebo in Treatment of MDD	Phase 2
Completed	`NCT02380066` - Comparison of Anyu Peibo With Placebo in Treatment of MDD	Phase 2
Completed	`NCT01187407` - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment	Phase 3